Analysis of Galapagos share price

Of course, we will have to keep a close eye on the development of the pipeline and its diversification with the studies conducted on promising new treatment candidates and the various results of clinical trials in different phases. Of particular note here are the trials conducted on the group's flagship products such as Filgotinib for the treatment of rheumatoid arthritis or Crohn's disease and GLPG1205, which targets inflammatory diseases of the small intestine in general.

Another important element to be monitored as part of this fundamental analysis concerns the positioning of this company internationally. We will therefore follow the research partnerships set up by the group and the creation of new research units in different countries.

Of course, you should also keep an eye on the financial health of the company with data on its market capitalization and cash flow. Of course, the costs of research and development and their weight in the company's financial results will be taken into account.

The forecasts and advice of analysts specializing in the biotech sector also often carry a lot of weight in the medium and long-term direction of this stock. You should therefore keep a close eye on this data.

Finally, we will of course also keep a close eye on the direct competition of the Galapagos company with all the news and advances made by the two major companies that we will present below and that carry out research on the same segments as this group.

Vertex Pharmaceuticals 

This American biotechnology company has existed since 1989 and is listed on the American stock market and on the Nasdaq 100 stock market index. It produces Ivacaftor for the treatment of cystic fibrosis and Telaprevir for the treatment of hepatitis C. Ivacaftor is thus successfully indicated for a rare form of cystic fibrosis, but not for its most common form. It is also known as one of the most expensive treatments in the world, costing nearly 220,000 euros per year per patient.

AbbVie 

Finally, the second most serious competitor to Galapagos is the American group AbbVie, which also specialises in pharmaceutical research. Abbvie is responsible for the research and development of therapeutic drugs for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of cystic fibrosis, low testosterone levels and complications associated with chronic kidney disease.

Pharnext

First of all, let's talk about the partnership signed by Galapagos with Pharnext, a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases. This partnership is a research and development partnership aimed at creating a new pipeline of synergistic drug combinations covering a wide range of indications. The partnership therefore builds on the research capabilities of both companies and leverages Pharnext's disruptive technology platform, Pleotherapie, which has already discovered and patented low-dose repositioned synergistic drug combinations in new indications and aims to accelerate the development of more effective and safe treatments that address unmet medical needs.

Gilead 

Another partnership, financial this time, was signed with the Gilead group, which will pay 3.95 billion dollars to Galapagos and will devote 1.1 billion dollars to the purchase of shares in this company. Thus, Gilead will pay an investment of 140.59 per share and increase its stake in the company from 12.3% to 22%. This price per share represents a 10% premium over the closing price of 128.15 euros just before this announcement. This partnership between Gilead and Galapagos is the second of its kind, as a previous agreement worth $2 billion was signed in 2015.